Zenas BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZBIO research report →
Companyzenasbio.com
Zenas BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
- CEO
- Leon Oliver Moulder Jr.
- IPO
- 2024
- Employees
- 130
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $873.21M
- P/E
- -2.56
- P/S
- 0.00
- P/B
- 3.24
- EV/EBITDA
- -1.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -167.71%
- ROIC
- -61.53%
Growth & Income
- Revenue
- $10.00M · 100.00%
- Net Income
- $-377,737,000 · -140.62%
- EPS
- $-8.44 · -124.47%
- Op Income
- $-211,385,000
- FCF YoY
- -43.86%
Performance & Tape
- 52W High
- $44.60
- 52W Low
- $8.91
- 50D MA
- $20.76
- 200D MA
- $24.46
- Beta
- -0.58
- Avg Volume
- 708.09K
Get TickerSpark's AI analysis on ZBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | MOULDER LEON O JR | buy | 60,000 |
| Apr 29, 26 | MOULDER LEON O JR | buy | 35,000 |
| Apr 28, 26 | MOULDER LEON O JR | buy | 25,000 |
| Mar 31, 26 | Lu Hongbo | buy | 3,768 |
| Mar 31, 26 | Fairmount Funds Management LLC | buy | 150,000 |
| Mar 31, 26 | MOULDER LEON O JR | buy | 34,000 |
| Mar 30, 26 | MOULDER LEON O JR | buy | 20,000 |
| Mar 31, 26 | Lu Hongbo | buy | 75,000 |
| Feb 11, 26 | Lu Hongbo | buy | 25,985 |
| Feb 13, 26 | Allen Patricia L | buy | 4,160 |
Our ZBIO Coverage
We haven't published any research on ZBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZBIO Report →